



zurabio

Zura Bio Announces Participation in June Investor Conferences

May 29, 2024 10:00 AM EDT

HENDERSON, Nev.--(BUSINESS WIRE)--May 29, 2024-- [Zura Bio Limited](#) (Nasdaq: ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June.

Conference Details:

Event: Jefferies Global Healthcare Conference

Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetings on Thursday, June 6, 2024, in New York, NY.

Event: Oppenheimer Novel Targets in Immunology Summit

Details: Robert Lisicki, Chief Executive Officer, will participate in a "Novel Immunological Mechanisms for Dermatological Disorders" panel discussion and one-on-one meetings on Monday, June 24, 2024, in New York, NY.

ABOUT ZURA BIO

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.



View source version on [businesswire.com](https://www.businesswire.com/news/home/20240529218969/en/): <https://www.businesswire.com/news/home/20240529218969/en/>

Megan K. Weinshank
Head of Investor Relations
ir@zurabio.com

Lee M. Stern
Meru Advisors
lstern@meruadvisors.com

Source: Zura Bio Limited